Filtered By:
Condition: Huntington's Disease

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 63 results found since Jan 2013.

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Conclusions MDSC are major players in the immunosuppressive scenario in cancer, thanks to their phenotype heterogeneity and critical interaction with several innate immune cells, thus representing a crucial target in oncology. Here we reviewed the interactions of MDSCs with NK cells. The contribution of key cytokines, chemokines and mediators active in this process have been discussed. We also described the contribution of MDSC on angiogenesis directly or indirectly through interactions with NK and immunosuppressive activities. A parallel of the cancer associated to the decidual counterpart of these cells is discussed, a...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

BGRF and SILS scientists analyze viability of shRNA therapy for Huntington's Disease
(Biogerontology Research Foundation) Researchers from the Biogerontology Research Foundation, Department of Molecular Neuroscience at the Swammerdam Institute for Life Sciences at the University of Amsterdam, and the Department of Neurobiology, Care Sciences and Society at the Karolinska Institute announce the publication of a paper in Translational Neurodegeneration, a BioMedCentral journal, titled RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA.
Source: EurekAlert! - Medicine and Health - December 1, 2017 Category: International Medicine & Public Health Source Type: news

RNAi mechanisms in Huntington ’s disease therapy: siRNA versus shRNA
AbstractHuntington ’s Disease (HD) is a genetically dominant trinucleotide repeat disorder resulting from CAG repeats within the Huntingtin (HTT) gene exceeding a normal range (>  36 CAGs). Symptoms of the disease manifest in middle age and include chorea, dystonia, and cognitive decline. Typical latency from diagnosis to death is 20 years. There are currently no disease-modifying therapies available to HD patients. RNAi is a potentially curative therapy for HD. A popular line of research employs siRNA or antisense oligonucleotides (ASO) to knock down mutant Huntingtin mRNA (mHTT). Unfortunately, this modality requ...
Source: Translational Neurodegeneration - November 27, 2017 Category: Neurology Source Type: research

Knockdown of HIP1 expression promotes ligand ‑induced endocytosis of EGFR in HeLa cells.
In this study, the effects of HIP1 on the degradation of EGFR, which have important roles in carcinogenesis after EGF stimulation, were examined. After screening 17 cell lines, the coexpression of HIP1 and EGFR was detected in HeLa cells. Accordingly, the expression of HIP1 was knocked down in HeLa cells using various HIP1 siRNA sequences. The endocytosis of EGFR and localization of clathrin in HeLa cells were examined after stimulation by EGF at various concentrations (i.e., 1.5 and 100 ng/ml). After HIP1 expression was blocked by siRNAs, EGFR endocytosis was accelerated and this effect was dependent on the EGF concentra...
Source: Oncology Reports - October 20, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

GSE98739 RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements
We report an analytical approach to integrate ordinal clinical information with transcriptomics. We have applied this method to public data for a large cohort of Huntington ’s disease patients and controls, identifying and prioritizing phenotype-associated genes. To validate the approach, we have performed viability, siRNA knockdown, mRNA-seq, and ChIP-seq on striatal precursor cells expressing either full-length wild type (STHdh Q7) or mutant huntingtin (STHdh Q111) . We have verified the role of a high-ranked gene in dysregulation of sphingolipid metabolism in the disease and demonstrated that inhibiting the enzyme, SP...
Source: GEO: Gene Expression Omnibus - May 11, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

GSE98738 ChIP-seq dataset for H3K9ac in Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements
We report an analytical approach to integrate ordinal clinical information with transcriptomics. We have applied this method to public data for a large cohort of Huntington ’s disease patients and controls, identifying and prioritizing phenotype-associated genes. To validate the approach, we have performed viability, siRNA knockdown, mRNA-seq, and ChIP-seq on striatal precursor cells expressing either full-length wild type (STHdh Q7) or mutant huntingtin (STHdh Q111) . We have verified the role of a high-ranked gene in dysregulation of sphingolipid metabolism in the disease and demonstrated that inhibiting the enzyme, SP...
Source: GEO: Gene Expression Omnibus - May 11, 2017 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Mus musculus Source Type: research

Coupling of d2R short but not d2R Long receptor isoform to the Rho/Rock signaling pathway renders striatal neurons vulnerable to mutant huntingtin
This article is protected by copyright. All rights reserved.
Source: European Journal of Neuroscience - August 31, 2016 Category: Neuroscience Authors: Beatriz Galan ‐Rodriguez, Elodie Martin, Emmanuel Brouillet, Nicole Déglon, Sandrine Betuing, Jocelyne Caboche Tags: Special Issue Article Source Type: research

SIRT2 regulates insulin sensitivity in insulin-resistant neuronal cells.
In this study, we report the role of SIRT2 in regulating insulin-sensitivity in neuronal cells in vitro. Using approaches like pharmacological inhibition of SIRT2, siRNA mediated SIRT2 knockdown and over-expression of wild-type and catalytically-mutated SIRT2, we observed that downregulation of SIRT2 ameliorated the reduced activity of AKT and increased insulin-stimulated glucose uptake in insulin resistant neuro-2a cells. The data was supported by over expression of catalytically-inactive SIRT2 in insulin-resistant human SH-SY5Y neuronal cells. Data highlights a crucial role of SIRT2 in regulation of neuronal insulin sens...
Source: Biochemical and Biophysical Research communications - May 5, 2016 Category: Biochemistry Authors: Arora A, Dey CS Tags: Biochem Biophys Res Commun Source Type: research

Abstract 4360: Validation of phosphodiesterase 10A as a cancer target
Phosphodiesterase 10A (PDE10) is a cAMP and cGMP degrading PDE isozyme that is highly expressed in the brain striatum where it plays an important role in cognition and psychomotor activity. PDE10 inhibitors are being developed for the treatment of schizophrenia and Huntington's disease and are generally well tolerated, likely because of low expression levels in peripheral tissues. We recently reported high levels of PDE10 in tumors and that genetic silencing by siRNA inhibits tumor cell growth with a high degree of selectivity over normal cells (Li et al., Oncogene 2014). These observations suggest that PDE10 may have an u...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lee, K., Li, N., Chen, X., Zhu, B., Yet, L., Madeira da Silva, L., Russo, S., Keeton, A. B., Boyd, M. R., Piazza, G. A. Tags: Experimental and Molecular Therapeutics Source Type: research

Neurodegenerative disorders: New Huntington disease target identified
Nature Reviews Drug Discovery 14, 386 (2015). doi:10.1038/nrd4652 Author: Sarah Crunkhorn Huntington disease (HD) is caused by the expansion of a CAG repeat tract in the gene encoding huntingtin (HTT), resulting in aggregation of a toxic mutant HTT protein (mHTT). Using an siRNA-based screen in human cultured cells, followed by hit validation in Drosophila melanogaster,
Source: Nature Reviews Drug Discovery - May 15, 2015 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research

siRNA screen identifies QPCT as a druggable target for Huntington's disease
Nature Chemical Biology 11, 347 (2015). doi:10.1038/nchembio.1790 Authors: Maria Jimenez-Sanchez, Wun Lam, Michael Hannus, Birte Sönnichsen, Sara Imarisio, Angeleen Fleming, Alessia Tarditi, Fiona Menzies, Teresa Ed Dami, Catherine Xu, Eduardo Gonzalez-Couto, Giulia Lazzeroni, Freddy Heitz, Daniela Diamanti, Luisa Massai, Venkata P Satagopam, Guido Marconi, Chiara Caramelli, Arianna Nencini, Matteo Andreini, Gian Luca Sardone, Nicola P Caradonna, Valentina Porcari, Carla Scali, Reinhard Schneider, Giuseppe Pollio, Cahir J O'Kane, Andrea Caricasole & David C Rubinsztein
Source: Nature Chemical Biology - April 6, 2015 Category: Biology Authors: Maria Jimenez-SanchezWun LamMichael HannusBirte SönnichsenSara ImarisioAngeleen FlemingAlessia TarditiFiona MenziesTeresa Ed DamiCatherine XuEduardo Gonzalez-CoutoGiulia LazzeroniFreddy HeitzDaniela DiamantiLuisa MassaiVenkata P SatagopamGuido MarconiChi Tags: Article Source Type: research

Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease.
Abstract The sigma-1 receptor (SIGMAR1) is one of the endoplasmic reticulum (ER) chaperones, which participate in the degradation of misfolded proteins via the ER-related degradation machinery linked to the ubiquitin-proteasome pathway. ER dysfunction in the formation of inclusion bodies in various neurodegenerative diseases has also become evident. Recently, we demonstrated that accumulation of SIGMAR1 was common to neuronal nuclear inclusions in polyglutamine diseases including Huntington's disease. Our study also indicated that SIGMAR1 might shuttle between the cytoplasm and the nucleus. In the present study, w...
Source: Neurobiology of Disease - November 14, 2014 Category: Neurology Authors: Miki Y, Tanji K, Mori F, Wakabayashi K Tags: Neurobiol Dis Source Type: research

Abstract 1762: Phosphodiesterase 10, a novel target for colorectal cancer therapeutics
Phosphodiesterase 10 (PDE10) is a newly characterized PDE isozyme that is expressed in regions of the brain affecting cognition and psychomotor activity. Inhibitors are currently being developed for the treatment of schizophrenia and Huntington's disease, one of which, Pf-2545920 (MP-10), is in clinical trials. Although PDE10 is not expressed in most peripheral tissues, we recently found high levels in colon tumor cells compared with normal colonocytes and that genetic silencing by siRNA selectively suppressed colon tumor cell growth. These observations suggest that PDE10 may represent a novel anticancer target. Pf-2545920...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Lee, K. J., Li, N., Chen, X., Zhu, B., Yet, L., Piazza, G. Tags: Experimental and Molecular Therapeutics Source Type: research

Polyglutamine Disease Modeling: Epitope Based Screen for Homologous Recombination using CRISPR/Cas9 System
Discussion We show that CRISPR/Cas9 system can be utilized to perform homologous recombination in human cells to generate a HD isogenic allelic series (21, 72, 97 CAG). In our study, we compared the Cas9 vs. Cas9 D10A enzymes for their ability to mediate this event using two distinct endpoints. The use of Cas9 D10A is likely to be more selective with less off target effects. When we compared CRISPR-assisted HR using methylene blue stained clonal colonies it appeared that the wildtype Cas9 was much more effective at mediating HR. However, when we analyzed the same experiment in our 1C2 western blot assay which only detects ...
Source: PLOS Currents Huntington Disease - April 15, 2014 Category: Neurology Authors: mahrucan Source Type: research

Coenzyme Q10, Statin, and Spinocerebellar Ataxias (P6.047)
CONCLUSIONS:CoQ10 is associated with better clinical outcome in SCA1, 2, and 3 whereas statins are associated with worse clinical outcome in SCA6. These drug exposures did not appear to influence clinical progression within 2 years. CoQ10 and statins may have only symptomatic effects or require a longer period of time for disease modification.Study Supported by:American Brain Foundation Research Fellowship, Rare Disease Clinical Research Network RC1NS068897, and NINDS K08 NS083738.Disclosure: Dr. Kuo has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Figueroa has nothing to disclose. Dr. Pulst has received person...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kuo, S.-H., Lo, R., Figueroa, K., Pulst, S., Perlman, S., Wilmot, G., Gomez, C., Schmahmann, J., Paulson, H., Shakkottai, V., Ying, S., Zesiewicz, T., Bushara, K., Geschwind, M., Xia, G., Subramony, S., Ashizawa, T. Tags: Movement Disorders: Spinocerebellar Ataxias Source Type: research